Vesicular Stomatitis Virus Encoding Ebola Virus Glycoprotein

Summary

Vesicular Stomatitis Virus Encoding Ebola Virus Glycoprotein (CHEMBL6068375) is an approved vaccine component; indicated across 2 conditions including ebola hemorrhagic fever.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Vaccine component
• Indications: 2 conditions
• Clinical trials: 3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL6068375
Name	Vesicular Stomatitis Virus Encoding Ebola Virus Glycoprotein
Type	Vaccine component
Max phase	4

Also known as: Ervebo

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
Ebola hemorrhagic fever	4	MONDO:0005737	EFO:0007243

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE2	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06841614	PHASE3	NOT_YET_RECRUITING	EBOla Post-Exposure Prophylaxis
NCT05202288	PHASE2	NOT_YET_RECRUITING	Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers
NCT04822376	PHASE2	UNKNOWN	Prophylaxis Vaccine Antibodies Ebola

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).